Control Empresarial De Capital Buys 1,032,218 Shares of ProKidney Corp. (NASDAQ:PROK) Stock

ProKidney Corp. (NASDAQ:PROK) insider Control Empresarial De Capital bought 1,032,218 shares of the business’s stock in a transaction on Thursday, April 10th. The stock was bought at an average price of $0.61 per share, for a total transaction of $629,652.98. Following the transaction, the insider now directly owns 72,592,325 shares of the company’s stock, valued at approximately $44,281,318.25. This represents a 1.44 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.

ProKidney Trading Down 4.0 %

ProKidney stock opened at $0.71 on Wednesday. ProKidney Corp. has a 12 month low of $0.46 and a 12 month high of $4.44. The company has a market capitalization of $207.84 million, a PE ratio of -1.29 and a beta of 1.52. The stock has a 50-day moving average price of $1.08 and a two-hundred day moving average price of $1.53.

ProKidney (NASDAQ:PROK) last issued its quarterly earnings data on Monday, March 17th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.03). The company had revenue of $0.08 million for the quarter. As a group, analysts predict that ProKidney Corp. will post -0.57 earnings per share for the current fiscal year.

Hedge Funds Weigh In On ProKidney

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC raised its holdings in ProKidney by 1.3% during the 4th quarter. Geode Capital Management LLC now owns 2,231,930 shares of the company’s stock worth $3,773,000 after purchasing an additional 27,996 shares during the last quarter. Bleichroeder LP raised its stake in ProKidney by 8.4% during the fourth quarter. Bleichroeder LP now owns 2,000,000 shares of the company’s stock worth $3,380,000 after buying an additional 155,000 shares during the last quarter. State Street Corp lifted its holdings in ProKidney by 16.2% in the third quarter. State Street Corp now owns 1,428,318 shares of the company’s stock valued at $2,742,000 after buying an additional 198,836 shares during the period. Northern Trust Corp boosted its position in ProKidney by 7.4% during the fourth quarter. Northern Trust Corp now owns 890,907 shares of the company’s stock valued at $1,506,000 after acquiring an additional 61,206 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. grew its holdings in ProKidney by 48.5% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 844,277 shares of the company’s stock worth $740,000 after acquiring an additional 275,630 shares during the period. 51.59% of the stock is owned by institutional investors and hedge funds.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.